MHRA Alert – Amiodarone: Essential Monitoring and Supervision Reminder

Important Safety Reminder: Amiodarone Monitoring Requirements

Amiodarone is an effective antiarrhythmic agent, but it carries significant risks that demand careful patient supervision and regular monitoring. Healthcare professionals should ensure they are familiar with these risks and implement robust review protocols.

Key Safety Concerns

Amiodarone has been associated with serious and potentially life-threatening adverse effects affecting:

• Pulmonary toxicity – including pulmonary fibrosis and pneumonitis
• Hepatotoxicity – liver dysfunction and cirrhosis
• Thyroid dysfunction – both hypo- and hyperthyroidism

These complications can develop insidiously and may not be immediately apparent, making proactive monitoring essential.

Affected Medications

• Amiodarone (all formulations)
• Cordarone X (branded preparation)

Recommended Actions for Healthcare Professionals

• Ensure baseline investigations are completed before initiating treatment (pulmonary function, liver function tests, thyroid function)
• Establish a structured follow-up schedule with regular clinical review
• Monitor for signs and symptoms of organ toxicity at each review
• Repeat appropriate investigations at intervals recommended in product guidance
• Discuss risks and benefits with patients and document informed consent
• Consider alternative antiarrhythmic agents where appropriate

For the full MHRA drug safety update, visit the MHRA website.